S&P 500 Industrials Sector SEC Filings — May 22, 2026

22-05-2026

Pyrophyte Acquisition Corp. reported a net loss of $6.1M for Q3 2025 and $14.4M for the nine months ended September 30, 2025, compared to net income of $299K and $2.3M in the same periods of 2024, driven by a $5.3M and $14.0M unfavorable change in fair value of derivative warrant liabilities. The company experienced significant redemptions of Class A ordinary shares, with shares subject to possible redemption falling from 6,290,711 to 1,513,954, and cash held in trust decreasing from $73.8M to $18.7M. Total liabilities more than doubled to $33.8M, and the accumulated deficit widened to $33.7M, while cash on hand remained minimal at $7,958.

• · General and administrative expenses decreased 59.9% YoY to $110K in Q3 2025 and 63.1% to $519K for the nine-month period.
• · Gain on cash held in Trust Account fell 81.0% YoY to $147K in Q3 2025 and 68.7% to $1.0M for the nine-month period.
• · Net cash used in operating activities improved to $429K for nine months 2025 from $752K in 2024.
• · The company recorded a $868K change in fair value of conversion option liability in Q3 2025, with no comparable item in 2024.
• · Deferred underwriting fees payable remained unchanged at $8.4M.
• · The company is classified as an emerging growth company and a shell company.
• · Cash increased slightly from $1,173 to $7,958 during the nine-month period.

22-05-2026

Range Capital Acquisition Corp. filed an 8-K supplementing its definitive proxy statement to modify the terms of a proposed extension of its business combination deadline. The company now seeks shareholder approval to extend the deadline from 18 months post-IPO (June 23, 2026) to up to 27 months (March 23, 2027), with the sponsor depositing $0.03 per outstanding public share (up to $60,000) monthly for each one-month extension. The trust account held approximately $122.17 million as of May 21, 2026, implying a per-share redemption price of about $10.62, which matched the May 21 closing price. However, the company warns of potential insufficient liquidity for shareholders to sell shares in the open market at that price.

• · The Extraordinary General Meeting is scheduled for June 18, 2026.
• · The sponsor will receive a non-interest bearing, unsecured promissory note for each monthly deposit, payable upon consummation of a business combination.
• · The company will file a Form 8-K within four business days following each monthly contribution to the trust account.
• · The current deadline under the articles is June 23, 2026 (18 months from IPO closing on December 23, 2024).
• · The proposed amended deadline is March 23, 2027 (27 months from IPO).
• · The per-share redemption price of $10.62 is before deduction of taxes payable, if any.

22-05-2026

Lakewood-Amedex Biotherapeutics reported a net loss of $923,291 for Q1 2026, a 71% increase from the $539,617 loss in Q1 2025, driven by a sharp rise in general and administrative expenses to $703,444 (up 89% YoY). The company remains pre-revenue with zero revenue in both periods, and cash and cash equivalents fell 95% from $236,400 at year-end 2025 to just $11,709 at March 31, 2026, raising significant going-concern risks.

• · Net loss per share worsened from $(0.15) in Q1 2025 to $(0.20) in Q1 2026.
• · Interest expense surged to $38,219 in Q1 2026 from $1,315 in Q1 2025, a 2,806% increase, primarily due to related party notes.
• · Accounts payable increased to $547,829 at March 31, 2026 from $381,041 at December 31, 2025.
• · Accrued expenses and other current liabilities rose to $594,723 from $303,872.
• · Notes payable to related parties grew to $1,625,000 from $1,500,000.
• · Total current liabilities exceeded total current assets by $2,977,070 at March 31, 2026, indicating severe liquidity strain.
• · The company had an accumulated deficit of $54,274,421 and a stockholders' deficit of $2,841,648.
• · Series B cumulative dividends of $493,190 were declared in both Q1 2026 and Q1 2025, contributing to a net loss attributable to common stockholders of $1,416,481 in Q1 2026.
• · Cash used in operating activities improved slightly to $349,691 in Q1 2026 from $404,089 in Q1 2025.
• · No revenue was generated in either period; the company remains in the development stage.

22-05-2026

At its 2026 Annual Meeting on May 19, 2026, First Northwest Bancorp shareholders approved the Amended and Restated 2020 Equity Incentive Plan, increasing authorized shares from 520,000 to 820,000 and raising the annual non-employee director compensation limit from $150,000 to $175,000. However, Proposal 2 to remove supermajority provisions from the Articles of Incorporation failed, receiving only 67.37% of outstanding shares in favor, short of the required 80% threshold. All nine director nominees were elected with strong support (ranging from 87.26% to 93.34% of votes cast).

• · The Amended Plan will terminate 10 years after its effective date, unless terminated earlier by the Board.
• · Proposal 2 (removing supermajority provisions) received 6,399,941.98 votes for (98.85% of votes cast), 68,769.68 against, 5,679 abstain, and 1,267,289 broker non-votes, but failed because it required 80% of outstanding shares (approximately 7,599,440 shares).
• · Proposal 3 (Equity Incentive Plan) received 5,851,403.42 for (90.38%), 275,255.24 against, 347,732 abstain.
• · Proposal 4 (Say-on-Pay) received 5,480,183.31 for (84.64%), 583,739.24 against, 410,468.11 abstain.
• · Proposal 5 (Auditor ratification) received 7,285,594.98 for (94.11%), 392,092.68 against, 63,992 abstain, with zero broker non-votes.
• · All director nominees were elected with support ranging from 87.26% (Sherilyn G. Anderson) to 93.34% (Curt T. Queyrouze) of votes cast.

22-05-2026

Evolutionary Tree Capital Management, LLC disclosed 13F holdings valued at approximately $53.2M as of March 31, 2026, comprising 26 equity positions. Top holdings include Abbott Laboratories ($1.83M or 3.4% of portfolio), CACI International ($2.85M), Krystal Biotech ($3.18M), Netflix ($2.63M), and Alphabet ($4.25M). The fund's largest position by weight is Alphabet at $4.25M (8.0% of portfolio), followed by Krystal Biotech and CACI International, signaling a focus on healthcare, technology, and internet services.

• · The fund increased its position count to 26 holdings from 0 in prior filing (first-time 13F filer or new fund as no prior 13F data available for comparison).
• · Top 10 holdings by value: Alphabet ($4.25M), Krystal Biotech ($3.18M), CACI International ($2.85M), Meta Platforms ($2.78M), Netflix ($2.63M), Cellebrite DI ($2.53M), Micron Technology ($2.51M), Microsoft ($2.53M), Broadcom ($2.01M), Axon Enterprise ($2.08M).
• · Largest position by number of shares: Cellebrite DI Ltd with 183,473 shares (value $2.53M).
• · Smallest position by value: Shopify Inc at $859,402 (7,245 shares).
• · Sector concentration: Technology/Software (Broadcom, Microsoft, Palo Alto, Roblox, Rubrik, Samsara, Shopify, Tradeweb) and Healthcare/Biotech (Abbott, Ascendis Pharma, Krystal Biotech, Procept BioRobotics) dominate the portfolio.
• · No period-over-period comparison data is available as this is the first filing on record; no prior public 13F data for Evolutionary Tree Capital Management, LLC exists in this filing.

22-05-2026

The Estée Lauder Companies Inc. and Puig have terminated discussions regarding a potential business combination, as announced on May 21, 2026. The companies had confirmed on March 23, 2026 that they were in talks, but no agreement was reached, and there are no assurances regarding any future deal.

• · The discussions were first confirmed on March 23, 2026.
• · The termination was announced on May 21, 2026.
• · The filing is an amendment (8-K/A) to the original 8-K filed on March 23, 2026.
• · A press release dated May 21, 2026 is attached as Exhibit 99.1.

22-05-2026

Janus Detroit Street Trust filed additional proxy soliciting materials (DEFA14A) urging shareholders to vote on a new investment advisory agreement following Janus Henderson's agreement to become a privately-owned company. The Board of Trustees unanimously recommends voting FOR the proposal, which would keep the same management team, fee rates, and investment objectives. The shareholder meeting has been adjourned to May 29, 2026, and the filing includes multiple scripts and templates for phone, text, and email outreach to encourage voting.

• · The definitive proxy statement was filed with the SEC on March 2, 2026.
• · Shareholders can vote by phone (1-855-206-2309), mail, text message link, or via the Proxy Vote Mobile App.
• · The Board of Trustees unanimously recommends voting FOR the proposal.
• · The meeting was originally scheduled for May 18, 2026, and has been adjourned to May 29, 2026.
• · Contact hours for voting: Mon-Fri 9:00am-10:00pm EST, Sat-Sun 10:00am-6:00pm EST.

22-05-2026

Denali Therapeutics and Biogen announced topline results from the Phase 2b LUMA study of BIIB122 (DNL151) in early-stage Parkinson's disease on May 21, 2026. The press release was furnished as an exhibit to the 8-K filing. No specific numerical results or performance metrics were disclosed in the filing itself.

• · The filing is an 8-K under Item 7.01 Regulation FD Disclosure.
• · The press release is furnished, not filed, and is not incorporated by reference into other SEC filings.
• · The study is in early-stage Parkinson's disease.
• · The filing date is May 22, 2026, with the event date of May 21, 2026.

22-05-2026

Access Investment Management LLC filed its Q1 2026 13F-HR, reporting total holdings valued at approximately $375.6 million across 157 equity positions. The portfolio shows significant concentration in financials and industrials, with top holdings including United Rentals ($23.3M), Sonoco Products ($15.7M), Apollo Global Management ($15.8M), and Citigroup ($13.5M).

• · The filing includes 157 equity positions with a total market value of $375,590,424 as of March 31, 2026.
• · Top 10 positions by value: United Rentals ($23.3M), Sonoco Products ($15.7M), Apollo Global Management ($15.8M), Citigroup ($13.5M), East West Bancorp ($13.5M), JPMorgan Chase ($10.4M), Bank of America ($10.2M), Donnelley Financial Solutions ($11.0M), Customers Bancorp ($9.7M), and Stifel Financial ($15.8M).
• · Largest holdings by share count: Integra LifeSciences (640,535 shares), Sally Beauty Holdings (563,855 shares), DXC Technology (497,670 shares), Ladder Capital Corp (483,796 shares), and Wiley John & Sons (366,520 shares).
• · The portfolio includes a mix of common stocks, ETFs, and ADRs across various sectors including financials, industrials, technology, healthcare, and consumer goods.
• · Notable ETF positions include iShares International Select Dividend ETF ($4.5M), iShares S&P Small-Cap 600 Value ETF ($3.9M), Vanguard FTSE Pacific ETF ($6.7M), and Vanguard International High Dividend Yield ETF ($2.0M).

22-05-2026

Amphenol Corporation held its annual meeting on May 21, 2026, with 1,121,383,291 shares present out of 1,229,430,709 outstanding. Stockholders elected all eight director nominees, ratified Deloitte & Touche as independent auditor, and approved the advisory vote on executive compensation. However, CEO R. Adam Norwitt received the lowest support among directors with 58,062,011 votes against (5.4% of votes cast), and the say-on-pay proposal had 83,096,067 votes against (7.7% of votes cast), indicating notable shareholder dissent.

• · Record date for the meeting was March 23, 2026.
• · Proxy Statement was filed with the SEC on April 8, 2026.
• · All director nominees received over 1 billion votes FOR, with Rita S. Lane receiving the highest support (1,066,823,967 FOR).
• · Ratification of Deloitte & Touche received 1,048,449,127 FOR and 72,154,410 AGAINST.
• · Advisory vote on executive compensation received 984,297,730 FOR and 83,096,067 AGAINST, with 5,323,917 abstentions.
• · Non-votes (broker non-votes) totaled 48,665,577 for each director election and the say-on-pay proposal.

22-05-2026

Dianthus Therapeutics held its 2026 Annual Meeting on May 21, 2026, where stockholders elected Sujay Kango, Anne McGeorge, and Jonathan Violin as Class II directors, approved executive compensation on an advisory basis, and ratified Deloitte & Touche as the independent auditor for fiscal 2026. All three proposals passed, with the auditor ratification receiving overwhelming support (46,298,319 for vs. 5,279 against). However, Anne McGeorge received a notable 8,404,137 withheld votes (19.4% of votes cast), indicating some shareholder dissent.

• · The Annual Meeting was held on May 21, 2026, and the proxy statement was filed on April 9, 2026.
• · All three Class II director nominees were elected, but Anne McGeorge received 8,404,137 withheld votes (19.4% of votes cast), significantly more than the other nominees.
• · The advisory vote on executive compensation passed with 41,004,507 for, 1,713,043 against, and 500,964 abstentions.
• · Ratification of Deloitte & Touche as independent auditor for fiscal year ending December 31, 2026 passed with 46,298,319 for, 5,279 against, and 500,471 abstentions, with no broker non-votes.
• · Broker non-votes totaled 3,585,554 on the director elections and executive compensation proposals.

22-05-2026

Byline Bancorp executed a Third Amendment to its credit agreement with CIBC Bank USA, extending the revolving loan maturity date to May 23, 2027 (previously May 2026). The company maintains an available $15M revolving credit facility, while the $20M term loan remains paid off. No new borrowing or financial deterioration was disclosed.

• · The Eleventh Amended Revolving Note was executed to reflect the new maturity date of May 23, 2027.
• · The original Loan Agreement was dated May 26, 2023 and had been amended twice before.
• · The negative pledge agreement (originally October 11, 2018) was affirmed and consented to by the company.
• · All collateral previously provided continues to secure the loan, and all guaranties remain in full force.
• · The amendment was effective May 24, 2026, but signed May 22, 2026.

22-05-2026

GE Vernova Inc. held its annual meeting on May 20, 2026, where stockholders elected three Class II directors (Matthew Harris, Martina Hund-Mejean, and Paula Rosput Reynolds) to three-year terms, approved executive compensation in a non-binding advisory vote, ratified Deloitte & Touche LLP as independent auditor for FY2026, and rejected a stockholder proposal requesting a report on sustainability goals using net-present-value and return-on-investment calculations. All director nominees received strong support with over 95% of votes cast in favor, while the sustainability proposal was overwhelmingly opposed with only 1.5% of votes cast in favor.

• · The annual meeting was held on May 20, 2026, and the proxy statement was filed on April 3, 2026.
• · All three director nominees were elected to serve until the 2029 annual meeting.
• · The sustainability proposal received only 2,895,955 votes in favor versus 187,794,281 against, indicating strong shareholder opposition.
• · Broker non-votes were 34,284,142 for all proposals except auditor ratification (which had no broker non-votes).
• · Auditor ratification received the highest support with 225,917,101 votes for and only 354,151 against.

22-05-2026

MetroCity Bankshares held its 2026 Annual Meeting on May 21, 2026, with 71.19% of outstanding shares represented. Shareholders elected four Class II directors and one new Class I director, ratified Crowe LLP as auditor, and voted to hold advisory votes on executive compensation every two years. All proposals passed, though director Francis Lai received significant votes against (2,656,568).

• · Director Francis Lai received 2,656,568 votes against, the highest among all directors.
• · Broker non-votes were 2,859,323 for most director elections and 15,980 for auditor ratification.
• · The board determined to hold future advisory votes on executive compensation every two years.

22-05-2026

Integer Holdings Corporation approved amendments to CEO Payman Khales' employment agreement and named executives' change of control agreements to provide accelerated vesting of performance-based equity awards upon qualifying termination around a change of control. The Board also approved $4,406,100 in aggregate retention bonuses for five executives, payable 50% on Dec 31, 2026 and 50% upon a change of control. Stockholders approved all four proposals at the May 20, 2026 Annual Meeting, including the 2026 Omnibus Incentive Plan (with 1,000,000 new shares plus rollover shares) and the election of all 11 directors, though several directors received notable withhold votes (up to 2.48 million shares withheld).

• · The 2026 Omnibus Incentive Plan expires on May 20, 2036 (10-year term).
• · All incentive compensation under the 2026 Plan is subject to clawback under the Company's Incentive Compensation Recoupment Policy.
• · Proposal 1 (Election of directors): All 11 nominees received majority FOR votes, but Tyrone Jeffers had 2,423,486 withheld, M. Craig Maxwell had 2,482,983 withheld, and Donald J. Spence had 2,430,264 withheld — representing approximately 8.3% of votes cast for those nominees.
• · Proposal 2 (Ratify auditor): FOR 30,439,879; AGAINST 523,970; ABSTAINED 8,137 — strong support.
• · Proposal 3 (Advisory say-on-pay): FOR 28,727,674; AGAINST 393,504; ABSTAINED 10,160; Broker NON-VOTE 1,840,648 — approved with ~98.6% support of votes cast (excluding broker non-votes).
• · Proposal 4 (2026 Plan): FOR 27,750,271; AGAINST 1,378,718; ABSTAINED 2,349; Broker NON-VOTE 1,840,648 — approved with ~95.3% support of votes cast (excluding broker non-votes).
• · The 2026 Plan also includes rollover of shares remaining available under the 2021 Plan plus shares subject to outstanding 2021 Plan awards that later become forfeited or lapse (in addition to the new 1,000,000 share reserve).

22-05-2026

SBA Communications Corporation held its 2026 Annual Meeting of Shareholders on May 22, 2026, where shareholders voted on three proposals. All three proposals were approved: the election of three Class III directors (Steven E. Bernstein, Laurie Bowen, and Amy E. Wilson), the advisory approval of named executive officer compensation, and the ratification of Ernst & Young LLP as the independent auditor for fiscal 2026. While all directors were elected, Laurie Bowen received a notable 10.7 million against votes (11.3% of votes cast), indicating some shareholder dissent.

• · Broker non-votes totaled 2,476,746 for each director proposal and the advisory compensation vote.
• · The ratification of Ernst & Young LLP had no broker non-votes.
• · All three proposals passed with majority support.

22-05-2026

Centessa Pharmaceuticals plc announced that the HSR Act waiting period expired on May 21, 2026, for its acquisition by Eli Lilly and Company. The closing remains subject to shareholder approval and court sanction. The acquisition is expected to close pending these conditions.

• · The HSR Act waiting period expired at 11:59 p.m. on May 21, 2026.
• · The Transaction Agreement was dated March 31, 2026.
• · A definitive proxy statement was filed on May 7, 2026.
• · The acquisition is structured as a court-sanctioned scheme of arrangement under Part 26 of the UK Companies Act 2006.
• · Centessa is not subject to the UK Takeover Code.

22-05-2026

TransCode Therapeutics, Inc. (RNAZ) received a Nasdaq deficiency letter on May 19, 2026, for failing to meet the minimum stockholders' equity requirement of $2,500,000, reporting only $1,251,427 in its March 31, 2026 10-Q. The company has until July 3, 2026, to submit a compliance plan, and may receive up to a 180-day extension, but faces significant risk of delisting if unable to regain compliance, which would materially adversely affect its operations and share value.

• · The deficiency letter was received on May 19, 2026, and the 8-K was filed on May 22, 2026.
• · The company has 45 calendar days (until July 3, 2026) to submit a compliance plan to Nasdaq.
• · If the compliance plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the deficiency letter to regain compliance.
• · If the plan is rejected or compliance is not achieved, the company may appeal to a Nasdaq Hearings Panel, which would stay any delisting action.
• · The company's common stock trades under the symbol RNAZ on the Nasdaq Capital Market.

22-05-2026

Waters Corporation held its annual meeting on May 21, 2026, with 90,729,508 shares (92.4% of eligible shares) represented. All 11 director nominees were re-elected, and stockholders ratified PricewaterhouseCoopers LLP as independent auditor for FY2026. The non-binding advisory vote on executive compensation passed with 76,557,521 votes in favor, though 10,653,534 voted against, indicating notable shareholder dissent.

• · Christopher A. Kuebler received the lowest support among directors with 82,799,542 for, 3,610,545 against, and 930,743 abstentions.
• · Flemming Ornskov, M.D., M.P.H. also faced notable opposition with 3,955,483 against and 280,693 abstentions.
• · The ratification of PricewaterhouseCoopers LLP as auditor was approved with 84,825,213 for, 4,979,244 against, and 925,052 abstentions.
• · The non-binding advisory vote on executive compensation had 10,653,534 votes against, representing approximately 12.2% of shares voted (excluding broker non-votes).

22-05-2026

Colony Bankcorp Inc. held its Annual Meeting on May 21, 2026, with 76.22% of outstanding shares represented. Shareholders elected eight directors, approved the advisory say-on-pay resolution, and ratified Mauldin & Jenkins as the independent auditor for 2026. All proposals passed with strong support, though the say-on-pay resolution received 350,535 votes against and 240,647 abstentions, indicating some shareholder dissent on executive compensation.

• · Proposal 1: All eight director nominees were elected with votes for ranging from 13,313,557 (Meagan M. Mowry) to 13,883,640 (Paul Joiner, III).
• · Proposal 2 (Say-on-Pay): 13,368,357 votes for, 350,535 against, 240,647 abstentions, and 2,179,441 broker non-votes.
• · Proposal 3 (Auditor Ratification): 15,991,044 votes for, 143,300 against, 4,636 abstentions, and no broker non-votes.
• · Broker non-votes were 2,179,441 for all director elections and the say-on-pay proposal, but zero for the auditor ratification.

22-05-2026

At its May 20, 2026 Annual Meeting, Babcock & Wilcox Enterprises (BWSN) stockholders approved an amendment to the 2021 Long-Term Incentive Plan, doubling authorized shares for awards from 5,250,000 to 10,250,000. However, a proposal to declassify the Board and move to annual director elections failed to achieve the required 80% supermajority vote (85.7M for vs. 0.4M against, with 16.3M broker non-votes), and a related proposal to reduce the supermajority voting threshold also failed. Directors Alan B. Howe and Rebecca L. Stahl were elected as Class II directors for three-year terms expiring at the 2029 annual meeting.

• · Proposal 1 (Board declassification) received 85,687,295 votes For, 410,247 Against, 736,626 Abstain, and 16,273,304 Broker Non-Votes — below the required 80% of all outstanding shares.
• · Proposal 4 (removal of 80% supermajority amendment provision) received 84,984,584 votes For, 1,052,507 Against, 797,077 Abstain, and 16,273,304 Broker Non-Votes — also failed.
• · Proposal 5 (ratification of BDO USA as auditor) passed overwhelmingly: 102,233,839 For, 63,515 Against, 810,118 Abstain.
• · Proposal 6 (non-binding advisory vote on executive compensation) passed: 77,165,838 For, 8,632,853 Against, 1,053,477 Abstain, 16,273,304 Broker Non-Votes.
• · Proposal 7 (Plan Amendment approval) passed: 75,348,044 For, 9,838,530 Against, 1,647,594 Abstain, 16,273,304 Broker Non-Votes.
• · Director Alan B. Howe received 71,226,304 votes For and 15,607,864 Withheld; Rebecca L. Stahl received 66,181,498 For and 20,652,670 Withheld (both with 16,273,304 Broker Non-Votes).

22-05-2026

James Alpha Funds Trust (d/b/a Easterly Funds Trust) filed a Rule 425 communication regarding the proposed reorganization of the Olstein Strategic Opportunities Fund and Olstein All Cap Value Fund into the Easterly Snow Small Cap Value Fund and Easterly Snow All Cap Value Fund, respectively. The filing reminds shareholders to complete their proxy vote and details service changes effective June 29, 2026, including a transfer of transfer agency services from U.S. Bank Fund Services to Ultimus Fund Solutions and a change of IRA custodian from US Bank to First National Bank of Omaha. No financial figures or performance metrics are provided in this communication.

• · Shareholder proxy vote is required; deadline not specified but reminder sent.
• · Account numbers will not change after the reorganization.
• · New mailing addresses for Easterly Funds Trust: overnight (225 Pictoria Drive, Suite 450, Cincinnati, OH 45246) and U.S. Mail (P.O. Box 46707, Cincinnati, OH 45246).
• · New contact center phone number: 833-999-2636, available Monday–Friday 8:30 a.m. to 6:00 p.m. ET, effective June 29, 2026.
• · Online access to Olstein accounts will cease at approximately 3 p.m. ET on June 26, 2026.
• · New online access for Easterly accounts begins June 29, 2026, via http://shareholder.ultimusfundsolutions.com/login/James%20Alpha%20Fund.
• · IRA custodian changes to FNBO effective on or about June 29, 2026; no action required from account holders.
• · Prospectus/Proxy Statement details class structure, sales charge schedules, CDSCs, exchange privileges, and purchase/redemption procedure comparisons.

22-05-2026

Kairos Pharma, LTD. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders to be held virtually on June 29, 2026. The Board recommends voting FOR all five proposals: election of directors, ratification of Weinberg & Company as auditor, a reverse stock split amendment, advisory approval of executive compensation, and an amendment to the 2023 Equity Incentive Plan. As of the May 15, 2026 record date, there were 21,411,198 shares of common stock outstanding.

• · The annual meeting will be held virtually at www.virutalshareholdermeeting.com/KAPA2026.
• · Stockholders of record as of May 15, 2026 are entitled to vote; each share gets one vote.
• · Proposal 2 (ratification of auditor) is considered routine under NYSE American rules, allowing broker discretionary voting.
• · Proposals 1, 3, 4, and 5 are non-routine; broker non-votes will not be counted on those proposals.
• · The deadline for internet voting is 11:59 p.m. ET on June 28, 2026.
• · A quorum requires a majority of the voting power of outstanding shares.
• · The proxy statement and annual report are accessible at www.proxyvote.com and kairospharma.com.

22-05-2026

Hope Bancorp held its 2026 annual meeting on May 21, 2026, with 88.53% of outstanding shares represented. All nine director nominees were elected, and stockholders approved the ratification of Crowe LLP as auditor (97% for) and the advisory vote on 2025 executive compensation (90% for). However, several directors received notable against votes, with Dale S. Zuehls receiving 16.9 million against votes (the highest), and the say-on-pay proposal had 10.8 million against votes, indicating some shareholder dissent.

• · All nine director nominees were elected, but Dale S. Zuehls received the most against votes at 16,922,313 (16.9 million), followed by Jinho Doo with 16,665,504 against.
• · Kevin S. Kim received 96,785,654 for and 9,944,582 against; Daisy Y. Ha received 97,000,135 for and 9,688,578 against.
• · The auditor ratification proposal had 3,522,166 against votes, while the say-on-pay proposal had 10,788,481 against votes.
• · Broker non-votes totaled 6,496,057 for each director election and the say-on-pay proposal, but zero for the auditor ratification (which is a routine matter).

22-05-2026

Leggett & Platt disclosed the termination of an Aircraft Time Sharing Agreement with CEO Karl G. Glassman, effective May 30, 2026, as the aircraft is expected to be sold. Shareholders approved the amendment and restatement of the Flexible Stock Plan, increasing shares available for future grant by 4.0 million to approximately 8.2 million, extending the plan term to 2036, and adding a non-employee director annual compensation limit of $750,000. All eight director nominees were elected, and the advisory Say-on-Pay vote passed with 94,779,810 votes for and 5,660,419 against.

• · The Aircraft Time Sharing Agreement was dated May 20, 2024 and filed as Exhibit 10.3 to the Company's Form 8-K on May 21, 2024.
• · The Flexible Stock Plan has a term of 10 years expiring in 2036.
• · The Plan amendments include a requirement for the CEO to hold for at least one year any net shares received from the exercise of stock options or stock appreciation rights.
• · Director Joseph W. McClanathan received the highest number of against votes (11,851,234) among director nominees.
• · The ratification of PwC as auditor received 115,178,397 votes for and 2,605,282 against, with no broker non-votes.
• · Say-on-Pay was approved with 94,779,810 votes for and 5,660,419 against, with 17,351,084 broker non-votes.

22-05-2026

Ibotta, Inc. appointed Jared Chomko as Principal Accounting Officer effective May 19, 2026, with no change to his compensation, while Matt Puckett stepped down from the interim role. At the 2026 annual meeting, shareholders elected two Class II directors (Amit Doshi and Larry Sonsini) and approved advisory say-on-pay and a one-year frequency for future votes, with strong support (over 94% of votes cast for each). The company also ratified KPMG as its independent auditor for fiscal 2026.

• · Jared Chomko, 37, has been with Ibotta since February 2021, previously serving as Controller and Vice President of Accounting; he holds a Bachelor's in Business Administration and a Master of Accountancy from Colorado State University and is a CPA.
• · There are no family relationships between Mr. Chomko and any executive officer or director, and no reportable transactions under Item 404(a).
• · The next required advisory vote on the frequency of say-on-pay will occur no later than the 2032 annual meeting.
• · Broker non-votes totaled 3,589,740 on Proposals 1, 2, and 3, representing about 23.1% of shares represented at the meeting.

22-05-2026

Banner Corporation held its Annual Meeting on May 20, 2026, with a quorum of 26,898,124 shares (79.4% of outstanding shares). All 12 director nominees were elected, and shareholders approved executive compensation (advisory) and ratified the appointment of Baker Tilly US, LLP as auditor for 2026. Notably, director Roberto R. Herencia received a significant 17.21% against vote, while all other directors received over 95% support.

• · Executive compensation advisory vote received 23,497,821 for, 1,331,515 against, and 18,628 abstentions.
• · Ratification of Baker Tilly US, LLP as auditor received 25,994,038 for, 872,392 against, and 31,693 abstentions.
• · Broker non-votes for director elections totaled 2,050,160 shares.
• · All directors elected for a one-year term expiring at the 2027 annual meeting.

22-05-2026

Terra Innovatum Global N.V. filed Amendment No. 2 to its Form 8-K to correct a typographical error in the compensation of Cesare Frepoli for FY2026, reducing it from EUR 5,000,000 to EUR 500,000. The filing also details directorship agreements for three executive directors (Petruzzi, Morichi, Frepoli) with fixed annual compensation for FY2025 and FY2026, and discloses subsidiary-level bonus payments totaling over EUR 500,000 and USD 231,402 to key officers for the successful Nasdaq listing.

• · The filing corrects a typographical error: Cesare Frepoli's FY2026 compensation was originally stated as EUR 5,000,000, now corrected to EUR 500,000.
• · Each directorship agreement has a one-year term ending after the 2026 annual general meeting, subject to annual renewals.
• · Change-in-control provisions entitle managers to 18 months of fixed compensation plus target bonus, continued healthcare for 18 months, and outplacement benefits.
• · Agreements include non-disparagement and 12-month non-solicitation restrictions.
• · Subsidiary bonus payments were approved on December 22, 2025, in recognition of the successful business combination and Nasdaq listing.
• · Additional subsidiary payments (totaling €197,700) were approved for Petruzzi, Cherubini, and Frepoli.

22-05-2026

NeoGenomics held its 2026 Annual Meeting on May 21, 2026, with 89.61% of outstanding shares represented. Stockholders approved all four proposals, including the election of nine directors, advisory approval of executive compensation (83.19% of votes cast in favor), an amendment to the 2023 Equity Incentive Plan to increase authorized shares by 5,000,000 (97.90% of votes cast in favor), and ratification of Deloitte & Touche as independent auditor (99.57% of votes cast in favor). However, the advisory vote on executive compensation showed notable opposition, with 16.80% of votes cast against it.

• · The record date for the Annual Meeting was March 23, 2026.
• · All nine director nominees were elected; Michael A. Kelly received the lowest votes for (104,709,238) and John P. Kenny the highest (110,028,235).
• · Broker non-votes totaled 6,257,933 on all proposals except the auditor ratification (which had no broker non-votes).
• · The advisory vote on executive compensation (Proposal 2) had 18,534,236 votes against and 56,118 abstentions.
• · The Equity Incentive Plan amendment (Proposal 3) had 2,308,922 votes against and 52,772 abstentions.
• · The auditor ratification (Proposal 4) had 494,869 votes against and 32,158 abstentions.

22-05-2026

FedEx Corporation announced the full redemption of all €354,878,000 outstanding aggregate principal amount of its 1.300% Notes due 2031, with a redemption date of May 28, 2026. The total redemption price is €358,619,289.16, which includes €3,741,289.16 of accrued and unpaid interest. This debt management action reduces the company's outstanding long-term debt and associated interest obligations.

• · The redemption date is May 28, 2026.
• · The redemption price is the greater of 100% of principal or present value of remaining payments discounted at comparable government bond rate plus 25 basis points.
• · The par call date for the notes is May 5, 2031.
• · The notes were originally issued with a 1.300% coupon rate.

22-05-2026

The filing reports the results of the 2026 Annual Meeting of Stockholders held on May 20, 2026. Stockholders approved a new 2026 Equity Incentive Plan, replacing the prior plan nearing expiration, with 4,000,000 shares reserved for issuance. Additionally, the 12 director nominees were re-elected, executive compensation was approved on a non-binding advisory basis, and Ernst & Young LLP was ratified as independent auditors for FY2026. No financial results were reported.

• · The 2026 Plan was approved by the Board on February 26, 2026, subject to stockholder approval.
• · The Company will file a Form S-8 to register shares under the 2026 Plan and a post-effective amendment to deregister shares under the Prior Plan.
• · All 12 director nominees were re-elected with votes ranging from 116 million to 124 million in favor.
• · Proposal 2 (Say-on-Pay) received 119,464,870 votes for and 5,518,957 votes against.
• · Proposal 4 (Auditor ratification) received 123,705,217 votes for and 6,650,693 votes against with no broker non-votes.

22-05-2026

Cathay General Bancorp filed an amendment to its Form 8-K to report that on May 21, 2026, the board appointed Ms. Lana Chan as a member of the Audit Committee and the Investment Committee of both the company and Cathay Bank, effective immediately. The board also determined that Ms. Chan qualifies as an audit committee financial expert under SEC rules. This amendment supplements the initial filing from February 5, 2026, which announced Ms. Chan's election to the boards but had not yet assigned her to any committees.

• · Ms. Chan was appointed to the Audit Committee and Investment Committee of both the company and Cathay Bank on May 21, 2026.
• · The board determined Ms. Chan qualifies as an 'audit committee financial expert' under Item 407(d)(5) of Regulation S-K.
• · This amendment updates the initial Form 8-K filed on February 5, 2026, which had not assigned Ms. Chan to any committees.

22-05-2026

Apogee Acquisition Corp announced that holders of its IPO units may elect to separately trade the underlying Class A ordinary shares, warrants, and rights commencing May 28, 2026. The separated securities will trade on Nasdaq under symbols AACP, AACPW, and AACPR, while undivided units will continue under AACPU. The company remains a blank-check company focused on acquiring technology-driven businesses, with no business combination completed yet.

• · Separate trading commences on May 28, 2026.
• · Each Unit consists of one Class A ordinary share, one redeemable warrant (exercise price $11.50), and one right to acquire one-fifth of one Class A ordinary share upon completion of a business combination.
• · The company's IPO registration statement became effective on April 6, 2026.
• · ARC Group Securities LLC acted as sole book-running manager for the IPO.
• · The company intends to focus on technology-driven businesses across software, hardware, compute infrastructure, engineered materials, intelligent systems, automation, energy, and other mission-critical platforms.

22-05-2026

On May 1, 2026, Generation Income Properties, Inc. (the Company), through indirect subsidiaries, entered into a $3.8M term loan with Hancock Whitney Bank at a fixed rate of 5.70% per annum, refinancing existing mortgage debt on two properties. The loan requires monthly payments of $23,986.17 and matures May 1, 2031, while the Company must maintain a minimum debt service coverage ratio of 1.15x. This refinancing was classified as an Other Event and did not involve any changes to core business performance, though the fixed interest rate is slightly elevated compared to market averages, and the transaction introduces financial covenants that could constrain operations if net operating income declines.

• · The loan replaces existing mortgage debt previously financed by Valley National Bank.
• · Prepayment is permitted without penalty.
• · Collateral includes two properties: 3815 South Orlando Drive, Sanford, FL (mortgage) and 5780 East Waterlevel Highway, Cleveland, TN (deed of trust), along with assignment of rents/leases.
• · The debt service coverage ratio covenant is measured annually at fiscal year-end based on net operating income from the two collateral properties.
• · Default events include non-payment, covenant breach, material misrepresentation, bankruptcy, material adverse change, or guarantor termination.
• · The initial monthly payment of $23,986.17 is based on a 25-year amortization schedule.
• · The loan is guaranteed by the Company and two Delaware special purpose entities.

22-05-2026

Hyatt Hotels Corporation announced the retirement of director Paul D. Ballew and the reduction of the Board from twelve to ten members, effective May 21, 2026. At the Annual Meeting held on May 20, 2026, stockholders elected three Class II directors, ratified Deloitte & Touche as auditor for fiscal 2026, and approved advisory say-on-pay compensation. A stockholder proposal requesting a report on plastics use was overwhelmingly rejected.

• · Gianni Marostica received 544,479,544 votes FOR and 100,306 WITHHELD; Heidi O'Neill received 543,282,927 FOR and 1,296,923 WITHHELD; Richard C. Tuttle received 528,192,732 FOR and 16,387,118 WITHHELD.
• · Ratification of Deloitte & Touche: 545,128,817 FOR, 877,697 AGAINST, 14,690 ABSTAIN.
• · Advisory say-on-pay approval: 541,786,817 FOR, 2,752,233 AGAINST, 40,800 ABSTAIN.
• · Stockholder proposal on plastics use report was rejected: 2,384,302 FOR, 541,909,225 AGAINST, 286,323 ABSTAIN.
• · Broker non-votes totaled 1,441,354 on director elections and the stockholder proposal.

22-05-2026

Orange County Bancorp, Inc. filed a Form 8-K on May 22, 2026, solely to furnish a press release dated the same day. The filing contains no financial statements, pro forma financial information, or shell company transactions, and no material financial figures or performance comparisons are disclosed.

22-05-2026

Molson Coors Beverage Company announced two debt offerings on May 20, 2026: USD-denominated senior notes due 2032 and CAD-denominated senior notes due 2033. The USD notes are being issued under an underwriting agreement with Citigroup, BofA Securities, and Goldman Sachs, while the CAD notes are being sold by a subsidiary to non-U.S. persons under Regulation S. Both issuances are expected to close on May 27, 2026.

• · The USD Notes are being issued under a base prospectus dated February 20, 2024, filed as part of an automatic shelf registration statement (File No. 333-277183).
• · The CAD Notes are being sold outside the United States to non-U.S. persons in reliance on Regulation S of the Securities Act.
• · The CAD Notes have not been registered under the Securities Act and may not be offered or sold in the U.S. except under an exemption.
• · The filing includes exhibits for the underwriting agreement (Exhibit 99.1) and the purchase agreement (Exhibit 99.2).

22-05-2026

Global Indemnity Group, LLC (GBLI) announced the appointment of Michele Colucci to its Board of Directors, effective May 18, 2026. Ms. Colucci, who previously served as a GBLI director from 2019 to 2021, brings expertise in digitalization, innovation, risk management, and technology. The filing contains no financial results or period-over-period comparisons.

• · Michele Colucci previously served as a GBLI director from 2019 to 2021.
• · She is the Founder and CEO of DigitalDx Ventures, a Silicon Valley venture capital firm focused on AI and personalized medicine diagnostics.
• · She also serves on the board of Fox Paine International GP, Ltd., the ultimate controlling party of GBLI.
• · Ms. Colucci holds a J.D. from Georgetown University and a Master's degree in Fine Arts from the American Film Institute.
• · GBLI's insurance carriers are each rated 'A' (Excellent) by AM Best.

22-05-2026

Welsbach Technology Metals Acquisition Corp. (WTMAU) reported a net loss of $440.3 million for Q1 2026, a dramatic increase from a $18.0 million loss in Q1 2025, driven primarily by a $425.2 million non-cash change in fair value of financial instruments. The company generated its first-ever revenue of $1.9 million following a business combination, but operating expenses surged to $16.1 million from $2.8 million, and cash used in operations increased to $5.6 million. Total stockholders' deficit improved significantly from -$654.9 million to -$10.8 million, largely due to the settlement of derivative liabilities and share issuances.

• · The company generated its first revenue of $1.9 million in Q1 2026, compared to zero in Q1 2025, following a business combination.
• · Gross profit was $0.4 million in Q1 2026, with cost of sales of $1.4 million.
• · Selling, general and administrative expenses surged to $16.1 million in Q1 2026 from $2.8 million in Q1 2025, a 475% increase.
• · The change in fair value of financial instruments resulted in a loss of $425.2 million in Q1 2026, up from $15.5 million in Q1 2025.
• · Cash used in operating activities increased to $5.6 million in Q1 2026 from $2.1 million in Q1 2025.
• · Cash and cash equivalents decreased by 53.9% from $11.7 million at December 31, 2025 to $5.4 million at March 31, 2026.
• · Total assets increased significantly from $22.5 million to $85.6 million, primarily due to the addition of $60.1 million in goodwill and $6.4 million in intangible assets.
• · Total liabilities decreased dramatically from $677.4 million to $96.4 million, mainly due to the settlement of the July Investment Agreement Derivative ($379.2 million) and CPU Share Allocation Obligation ($292.7 million).
• · Stockholders' deficit improved from -$654.9 million to -$10.8 million, driven by the issuance of common stock for settlement of derivative liabilities ($588.9 million) and CPU Share Allocation Obligations ($296.4 million), and a reclassification of CPU Share Allocation Obligation to equity ($186.8 million).
• · Non-trade accounts payable of $48.0 million and accrued expenses of $27.3 million represent significant current liabilities as of March 31, 2026.
• · The company had $3.5 million in short-term debt and $1.6 million in current portion of long-term debt as of March 31, 2026.
• · Net loss per share was -$0.72 in Q1 2026, compared to -$0.04 in Q1 2025.
• · Weighted average shares outstanding increased to 611.9 million in Q1 2026 from 454.7 million in Q1 2025.

22-05-2026

Richmond Mutual Bancorporation, Inc. (RMBI) announced a cash dividend of $0.15 per share on its common stock, payable on June 17, 2026, to shareholders of record as of June 3, 2026. The dividend was declared in a press release issued on May 22, 2026, as disclosed in an 8-K filing. No financial performance data or period-over-period comparisons are included in this filing.

• · Dividend payable on June 17, 2026
• · Record date is June 3, 2026
• · Filing type is 8-K under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits)
• · The filing does not contain any financial results, revenue, earnings, or period-over-period comparisons

22-05-2026

CCC Intelligent Solutions Holdings Inc. held its annual meeting on May 21, 2026, with 91.87% of voting power represented. Stockholders elected three Class II directors, approved an annual frequency for future say-on-pay votes, and ratified Deloitte & Touche LLP as the independent auditor for 2026. However, while the advisory say-on-pay proposal passed, 35,671,335 shares (about 7.0% of votes cast) were against it, indicating notable dissent.

• · The record date for the annual meeting was March 27, 2026.
• · Broker non-votes totaled 28,566,628 shares on the director election and both advisory compensation proposals.
• · The next advisory vote on the frequency of say-on-pay votes is required no later than the 2032 annual meeting.
• · Deloitte & Touche LLP was ratified as the independent auditor for the year ending December 31, 2026, with 515,649,326 votes for and 22,746,006 against.

22-05-2026

Quad/Graphics, Inc. held its 2026 annual meeting on May 20, 2026, with approximately 90.0% of all votes represented. Shareholders elected all nine director nominees and approved the compensation of named executive officers in an advisory vote, with strong support for both proposals.

• · Record date for shareholder determination was March 18, 2026.
• · Class A common stock has par value $0.025 per share and trades on NYSE under symbol QUAD.
• · Class B common stock has 10 votes per share, resulting in 132,619,830 votes from 13,261,983 shares.
• · No broker non-votes were reported for any director election or the advisory vote.
• · Abstentions on the advisory vote were 46,372 votes, which had no effect on the outcome.

22-05-2026

Destination XL Group, Inc. issued a press release on May 22, 2026, regarding its review of an unsolicited tender offer from Zodiac Partners II. The filing is a Regulation FD disclosure and does not include financial results or quantitative data.

• · The unsolicited tender offer is from Zodiac Partners II.
• · The company is reviewing the offer.
• · The press release is furnished as Exhibit 99.1.

22-05-2026

The Gabelli Dividend & Income Trust filed a proxy statement supplement on May 22, 2026, updating shareholders on the retention of Alliance Advisors, LLC to assist in proxy solicitation for the adjourned Annual Meeting (reconvened June 29, 2026). The fee for these services is up to $1.5 million, with approximately 45 employees involved. No financial results or period-over-period comparisons are provided in this filing.

• · Annual Meeting originally convened May 11, 2026, and adjourned to June 29, 2026 at 8:00 a.m. Eastern time.
• · Shareholders can contact Alliance Advisors toll-free at 1-866-206-7868 (U.S.) or 1-551-368-0034 (outside U.S.), or via email at GDV@allianceadvisors.com.
• · The supplement updates the 'Proxy Solicitation Expenses' section of the original Definitive Proxy Statement filed March 31, 2026.